Improved analogs and novel delivery systems for somatostatin octapeptides

Moreau, J.-P.; Kim, S.; Dong, J.Z.; Ignatious, F.; Jackson, S.; Moreau, S.C.; Morgan, B.A.; Touraud, F.; Taylor, J.E.; Tissier, B.; Pellet, M.; Davis, T.

« Previous Next »Metabolism - Clinical and Experimental
Volume 45, Supplement 1 , Pages 24-26, August 1996

Improved analogs and novel delivery systems for somatostatin octapeptides

J.-P. Moreau
- Address reprint requests to J.-P. Moreau, PhD, DSC Biomeasure Inc, 27 Maple St, Milford, MA 01757-3650.
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
S. Kim
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
J.Z. Dong
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
F. Ignatious
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
S. Jackson
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
S.C. Moreau
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
B.A. Morgan
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
F. Touraud
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
J.E. Taylor
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
B. Tissier
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
M. Pellet
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA
T. Davis
- Biomeasure Inc, Milford, MA, USA
- Pharma Biotech, Signes, France
- Tulane University Medical Center, New Orleans, LA ,USA
- University of Arizona, Tucson, AZ, USA

Abstract

Appropriate N-terminus modification can result in somatostatin (SRIF) octapeptide analogs that are both more potent and more selective in vitro for the human SRIF receptor type 2 (hsst₂). In addition, these modifications can improve the duration of action and bioavailability of SRIF analogs following parenteral administration, as shown by both pharmacological and distribution studies in vivo with BIM-23190 and BIM-23197 in the rat.

No full text is available. To read the body of this article, please view the PDF online.